• Recognised by the legal directories as one of the leading law firms for Life Sciences in Israel, our corporate and commercial Bio-tech and Medical Device Group advises on every commercial aspect relating to the business and innovation cycle of a life science company. We act for clients across the entire industry – including both innovative and generic manufacturers of pharmaceutical products, medical and healthcare start-ups, medical device developers, venture capital funds, academic institutions, healthcare providers and other entities that provide to the sector finance, services, technology and collaborative research and development.


    We advise founders and early stage companies on corporate structuring, licensing, founder agreements, incentive schemes, clinical trials, registrations, tax, obtaining and registering clear chain of IP title and, most importantly, preparing and successfully executing fund raising whether from angels or venture capital funds. For clients at a more developed stage, we advise on commercialisation of IP, the entering into of existing and potential markets, collaboration, technology transfers, routes of supply, further fund raising, management and exits (whether by way of M&A or an IPO).


    S. Horowitz & Co. is one of the few firms in Israel that has an in depth knowledge of the industry with the various skill sets and expertise to provide on-going advice on all legal and regulatory aspects concerning the development, testing, financing and commercialisation of pharmaceuticals and medical devices. Our understanding of the business and our expertise in the field makes us unique in Israel for being able to provide a multidisciplinary approach to the life science sector that can deliver more than just the core corporate capabilities.

    • Representing Spectranetics Corporation, a world leading manufacturer and supplier of medical equipment for use in minimally invasive interventional procedures, in its acquisition of Upstream Technologies Ltd., an Israeli company which specialises in developing new technologies for the manufacturing of medical equipment
    • Representing Radius Ventures, a US investment fund, on its investments in bio-tech companies in Israel (one such transaction includes acting for Radius on the sale of Medingo to Hoffman La Roche for $160 million plus $40 million additional milestone payments)
    • Representing Yeda Research and Development Limited (the commercialisation arm of the Weizmann Institute of Science, one of Israel’s largest and most prestigious research institutions) on a large number of technology transfer agreements in the biotech field, including research and licence agreements, evaluation and option agreements and consulting agreements
    • Representing AstraZeneca plc and Minrav Holdings Ltd. on their participation in a tender to establish a life science incubator as part of the Office of the Chief Scientist's incubator program
    • Representing Teva Pharmaceuticals (the world’s largest generic drug company) in a number of investments in drug development companies
    • Representing Medial Cancer Screening Ltd. a medical device and analytics start up:


    (i) on a US$ 15 million (based on a company pre-money valuation of US$80 million), Series A Preferred round financing made by the Chinese VC fund Horizon Ventures;

    (ii) on a US$ 5 million Series B Preferred round financing; and

    (iii) on all the company's day-to-day corporate and commercial legal requirements


    • Representing a group of angel investors on a large number of seed equity and debt investments in a variety of new biotech companies, with an emphasis on companies engaging in medical developments with meaningful contributions to society (such as the development of wearable medical equipment for the identification of congestive heart failure, an innovative scanner for use during oncological surgeries, a catheter for patients with heart diseases and a physiotherapy tool and communication software for children with special needs)
    • Represented Neusoft Group Ltd. (China’s largest IT and software company) on its acquisition of a controlling interest in Aerotel Medical Systems Ltd., a leading medical device company which designs and manufactures digital patient monitoring systems.
    • Representing Worthy Venture Resources LLC on its Series D Preferred investment in EarlySense Ltd., a medical-device company which developed a patient monitoring system
    • Representing AFS Technologies Inc., a company which develops solutions for optimising the manufacturing and supplying process for the food and beverage industry, in its acquisition of Visicom Ltd.
    • Representing Plenus, one of Israel's largest mezzanine finance houses for hi-tech companies, in connection with a series of mezzanine and equity financings in the biotech and hi-tech sectors